AMGN · Healthcare
AMGEN INC
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Product / Drug Pipeline ProgressImportance 34 · Surprise 42Amgen’s dazodalibep met the primary endpoint in the Phase 3 OASIZ 301 trial for systemic Sjögren’s disease, demonstrating statistically significant and clinically meaningful improvement in systemic disease activity.…
- Product Pipeline ProgressImportance 34 · Surprise 42Amgen’s dazodalibep met the primary endpoint in the Phase 3 OASIZ 301 trial for systemic Sjögren’s disease, demonstrating improved systemic disease activity. The company did not disclose the treatment difference versus…
- Revenue Performance and MixImportance 32 · Surprise 6Amgen reported approximately $10.1 billion of revenue in the second quarter. Newer products Repatha and EVENITY were reported to be offsetting declines from older medicines affected by patent expirations. The same…
News · 2026-09-22
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Amgen reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease. The CD40L antagonist met its primary endpoint, producing statistically significant…
- Product Pipeline ProgressImportance 31 · Surprise 42Amgen reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, meeting its primary endpoint with statistically significant and clinically…
News · 2026-09-21
- Licensing / Collaboration DealsImportance 31 · Surprise 42Veeva is expanding its decade-long partnership with Amgen through a planned global rollout of Vault CRM. The initiative would extend Amgen’s enterprise use of Veeva’s commercial customer-relationship-management…
- Partner Ecosystem ExpansionImportance 31 · Surprise 42Veeva is expanding its decade-long partnership with Amgen through a planned global rollout of Vault CRM. The deployment supports Amgen’s commercial operations and extends enterprise adoption of Veeva’s…
News · 2026-09-19
- Quarterly Dividend DeclarationImportance 37 · Surprise 6Amgen maintains a quarterly dividend of $2.52 per share, according to third-party reporting on September 19, 2026. The stated quarterly rate implies annualized dividend payments of $10.08 per share if unchanged. A…
News · 2026-09-17
- Lp(a) Drug Pipeline RiskImportance 34 · Surprise 42Novartis’s pelacarsen trial failed to meet its primary endpoint for reducing cardiovascular events, increasing clinical and regulatory uncertainty for the Lp(a)-lowering drug class. Amgen’s olpasiran faces heightened…
News · 2026-09-16
- Revenue Performance and MixImportance 53 · Surprise 48Amgen reported a 26% year-over-year increase in Q2 product sales across its six key growth drivers. Total revenue exceeded $10 billion in the quarter. The growth-driver portfolio includes products and pipeline programs…
- Product / Drug Pipeline ProgressImportance 49 · Surprise 66Amgen highlighted progress in its IMDELLTRA small-cell lung cancer program, including clinical-trial improvements and reduced monitoring requirements. The company also provided updates on its MariTide obesity program…
- Opdivo Biosimilar Patent LitigationImportance 40 · Surprise 42Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court to block the proposed biosimilar version of Opdivo. The plaintiffs allege that Amgen’s product would infringe several patents and are…
News · 2026-09-15
- Opdivo Biosimilar Patent LitigationImportance 37 · Surprise 42Bristol Myers Squibb and Ono Pharmaceutical filed a Delaware federal lawsuit against Amgen to block its proposed U.S. biosimilar of Opdivo. The plaintiffs allege that Amgen’s biosimilar infringes multiple…
- Competition and Pricing PressureImportance 26 · Surprise 24Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court to block its proposed U.S. biosimilar of the cancer immunotherapy Opdivo. The plaintiffs allege that Amgen’s biosimilar infringes patents…
News · 2026-09-14
- Regulatory Approval MilestonesImportance 31 · Surprise 42The FDA approved an update to IMDELLTRA (tarlatamab-dlle) labeling on September 14, 2026. The update substantially reduces the recommended monitoring time for the first two doses in an appropriate healthcare setting.…
- IMDELLTRA Pipeline ProgressImportance 31 · Surprise 42The FDA approved an update to IMDELLTRA (tarlatamab-dlle) prescribing information that substantially reduces the recommended monitoring time for the first two doses. The change is intended to support broader access to…
- IMDELLTRA Regulatory Approval MilestonesImportance 31 · Surprise 42On September 14, 2026, the U.S. Food and Drug Administration approved an update to Amgen’s IMDELLTRA (tarlatamab-dlle) Prescribing Information. The update substantially reduces the recommended monitoring time for the…
News · 2026-09-13
- IMDELLTRA Pipeline ProgressImportance 34 · Surprise 42Third-party reporting cited new Phase 3 IMDELLTRA data in lung cancer showing improved overall survival and progression-free survival. The data may strengthen Amgen’s 2027 growth narrative and reshape investor…
- Manufacturing Capacity ExpansionImportance 17 · Surprise 24The report identified manufacturing capacity for Amgen’s obesity drugs as a key risk to the company’s 2027 growth case. This suggests potential capacity constraints could affect the scalability of the obesity-drug…
News · 2026-09-12
- Revenue Performance and MixImportance 37 · Surprise 6Amgen reported second-quarter revenue of $10.05 billion. The company said Q2 revenue exceeded analyst estimates. Adjusted Q2 earnings per share were $6.29 alongside the reported revenue result.
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Amgen declared a quarterly dividend of $2.52 per share. The dividend was reported together with Q2 adjusted EPS of $6.29. The company also reported Q2 revenue of $10.05 billion when announcing the dividend.
News · 2026-09-11
- Revenue Performance and MixImportance 53 · Surprise 48Amgen reported 26% year-over-year growth across six key commercial drivers. Total revenue increased 10% year over year to more than $10 billion. The six-driver performance contributed materially to the revenue increase…
- Free Cash FlowImportance 38 · Surprise 6Amgen generated more than $8.1 billion in free cash flow during its latest fiscal year. The reported cash generation was cited as evidence of Amgen’s financial stability relative to clinical-stage biotechnology…
- IMDELLTRA Lung Cancer ResultsImportance 31 · Surprise 42Amgen highlighted IMDELLTRA’s momentum after a late-stage study in small-cell lung cancer showed improved overall survival, including in combination with AstraZeneca’s Imfinzi. The results strengthen IMDELLTRA’s…
- MariTide Pipeline ProgressImportance 31 · Surprise 42Amgen highlighted MariTide’s potential in obesity and related conditions, with a differentiated dosing schedule and substantial weight loss reported in a Phase II study. The company also identified possible…
- IMDELLTRA Pipeline ProgressImportance 31 · Surprise 42Amgen’s IMDELLTRA showed improved overall survival in a Phase III study for small-cell lung cancer. Amgen is seeking to reduce patient-monitoring requirements, which could improve access and support broader…
News · 2026-09-10
- Guidance and OutlookImportance 51 · Surprise 60Third-party reporting states that Amgen raised its full-year 2026 revenue and earnings-per-share guidance. The increase reflects management’s greater confidence after a second-quarter growth rebound and double-digit…
- Revenue Performance and MixImportance 45 · Surprise 40Amgen reported Q2 2026 revenue of $10.05 billion, exceeding analyst expectations. Twenty-two products delivered at least double-digit sales growth during the quarter. Tezspire and Repatha were identified as key growth…
- Market Demand TrendsImportance 36 · Surprise 40Amgen reported a broad growth rebound in the second quarter, with 22 products achieving at least double-digit sales growth. Tezspire and Repatha were identified as key accelerating products, indicating stronger demand…
- Product Pipeline ProgressImportance 34 · Surprise 42Amgen and AstraZeneca reported survival benefits for the Imdelltra-Imfinzi combination in first-line extensive-stage small-cell lung cancer. The results could support broader use of Imdelltra beyond its current…
- IMDELLTRA Lung Cancer ResultsImportance 34 · Surprise 42Amgen and AstraZeneca reported that the IMDELLTRA-Imfinzi combination produced a survival benefit in first-line extensive-stage small-cell lung cancer. The result could expand IMDELLTRA’s use beyond its current…
- Quarterly Dividend DeclarationImportance 3 · Surprise 6Amgen announced a quarterly dividend of $2.52 per share. The dividend was reported alongside Q2 adjusted earnings of $6.29 per share and revenue of $10.05 billion. The declaration represents a recurring cash…
News · 2026-09-09
- IMDELLTRA Lung Cancer ResultsImportance 52 · Surprise 42On September 9, 2026, Amgen and AstraZeneca reported that a late-stage study of Imdelltra plus Imfinzi improved overall survival, progression-free survival, and response rates in patients with extensive-stage…
- Revenue Performance and MixImportance 36 · Surprise 14Amgen reported second-quarter revenue of $10.05 billion, up 9.5% year over year. Quarterly earnings were $6.29 per share, exceeding analyst estimates. The reported revenue increase exceeded the $302 million materiality…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Amgen declared a quarterly dividend of $2.52 per share on September 9, 2026. The dividend declaration represents a recurring cash distribution to shareholders. The digest did not report an aggregate dividend amount,…
News · 2026-09-08
- Lp(a) Drug Pipeline RiskImportance 37 · Surprise 42Novartis's Phase III pelacarsen trial lowered lipoprotein(a), but failed to reduce cardiovascular events, raising questions about the efficacy of the broader Lp(a)-lowering drug class. The setback directly affects…
- Olpasiran Pipeline RiskImportance 37 · Surprise 42Novartis' Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering lipoprotein(a), raising uncertainty for Amgen's comparable olpasiran program. Third-party reports said the result challenged…
- IMDELLTRA Lung Cancer ResultsImportance 34 · Surprise 42Amgen reported positive Phase III DeLLphi-305 results for IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's Imfinzi (durvalumab) in first-line extensive-stage small cell lung cancer. The combination produced a…
News · 2026-09-07
- Revenue Performance and MixImportance 24 · Surprise 14Amgen reported second-quarter 2026 revenue of $10.05 billion, exceeding analyst estimates. Revenue increased 9.5% year over year. Adjusted EPS was $6.29 for the quarter, also above expectations. The reported growth was…
News · 2026-09-04
- Repatha Cardiovascular Outcomes DataImportance 54 · Surprise 74Amgen reported secondary VESALIUS-CV analysis showing Repatha reduced all-cause mortality by 20% and myocardial infarction risk by 36% in high-risk adults without a prior heart attack or stroke. The findings support…
News · 2026-09-03
- Repatha Cardiovascular Outcomes DataImportance 54 · Surprise 74Amgen reported secondary VESALIUS-CV analysis showing Repatha reduced all-cause mortality by 20% and myocardial infarction risk by 36% in high-risk adults without a prior heart attack or stroke. The findings support…
- Tavneos Regulatory Withdrawal RiskImportance 44 · Surprise 60UK regulators suspended Tavneos for new patients after identifying unreliable study data, creating a country-specific regulatory risk for Amgen. The suspension was cited repeatedly in third-party coverage as a headwind…
News · 2026-09-02
- Product / Drug Pipeline ProgressImportance 34 · Surprise 42Amgen reported positive interim Phase 3 DeLLphi-305 results for IMDELLTRA combined with AstraZeneca's Imfinzi versus durvalumab alone in first-line extensive-stage small-cell lung cancer. The combination met its…
- Revenue Performance and MixImportance 24 · Surprise 14Amgen reported second-quarter 2026 revenue of $10.05 billion, exceeding analyst estimates. Revenue increased 9.5% year over year. Adjusted EPS was $6.29 for the quarter, also above expectations. The reported growth was…
News · 2026-09-01
- Tavneos Withdrawal RiskImportance 47 · Surprise 60The UK's medicines regulator suspended Amgen's Tavneos for new patients because unreliable data from the main study could no longer establish efficacy or a favorable benefit-risk balance. The regulator plans to revoke…
- Tavneos Regulatory Withdrawal RiskImportance 47 · Surprise 60The United Kingdom’s medicines regulator suspended Amgen’s Tavneos for new patients after finding unreliable data in the drug’s main study. The regulator said the trial could no longer establish Tavneos’s efficacy or…
- Revenue Performance and MixImportance 42 · Surprise 14Amgen reported quarterly revenue of $10.05 billion, up 9.5% year over year. Quarterly EPS was $6.29, and the company exceeded earnings expectations. The digest did not provide segment revenue or product-mix details.
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Amgen announced a quarterly dividend of $2.52 per share. The reported dividend implied an annualized yield of approximately 2.3%. The digest did not state the dividend record date, payment date, or total…
News · 2026-08-31
- Repatha Cardiovascular Outcomes DataImportance 53 · Surprise 84Amgen reported that Repatha (evolocumab) reduced all-cause mortality risk by 20% in a Phase 3 study of more than 12,000 high-risk adults without a prior heart attack or stroke. The treatment was evaluated when added to…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Amgen announced a quarterly dividend of $2.52 per share. The dividend announcement was cited alongside the company’s recent quarterly results and earnings performance. The digest provided no payment date, record date,…
News · 2026-08-29
- Free Cash FlowImportance 37 · Surprise 6Amgen reported nearly $8.1 billion in free cash flow for fiscal 2025. The reported amount exceeded the materiality threshold of $302 million. The fiscal 2025 free-cash-flow figure indicates substantial cash generation…
News · 2026-08-27
- Revenue Performance and MixImportance 36 · Surprise 14Amgen reported quarterly revenue of approximately $10.05 billion, exceeding analyst expectations. Revenue increased 9.5% year over year, implying an increase of roughly $0.87 billion from the prior-year quarter. The…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Amgen and AstraZeneca reported positive top-line Phase 3 CROSSING results for TEZSPIRE (tezepelumab-ekko) in eosinophilic esophagitis (EoE) on August 27, 2026. TEZSPIRE achieved statistically significant improvements…
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Amgen declared a quarterly dividend of $2.52 per share. The dividend declaration was reported alongside the company’s quarterly earnings and revenue results. The digest did not specify the record date, payment date, or…
News · 2026-08-26
- Revenue Performance and MixImportance 36 · Surprise 14Amgen reported second-quarter revenue of $10.05 billion, up 9.5% year over year. Adjusted EPS was $6.29 for the quarter, exceeding analyst expectations. The digest does not provide segment revenue or geographic mix…
- Quarterly Dividend DeclarationImportance 10 · Surprise 6Amgen declared a quarterly dividend of $2.52 per share. The dividend implies an annualized per-share payout of $10.08 and a reported annual yield of approximately 2.3%. The declaration was reported alongside the…
News · 2026-08-25
- Licensing / Collaboration DealsImportance 52 · Surprise 42Amgen terminated its May 2023 research collaboration and license agreement with TScan Therapeutics for Crohn’s disease, effective November 10, 2026. The termination ends Amgen’s exclusive rights to TScan’s T-cell…
- Revenue Performance and MixImportance 31 · Surprise 6Amgen reported quarterly revenue of $10.05 billion. Quarterly EPS was $6.29. The reported results exceeded analyst expectations.
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Amgen declared a quarterly dividend of $2.52 per share. The dividend was announced alongside quarterly results reporting $10.05 billion of revenue. The announcement provides a stated per-share cash distribution for the…
News · 2026-08-24
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Amgen is advancing injectable tarlatamab into Phase 3 trials, supporting its oncology pipeline. MariTide is identified as a leading growth driver in the company’s broader pipeline and obesity-drug strategy. The…